Re-Assessing the Role of Platelet Activating Factor and Its Inflammatory Signaling and Inhibitors in Cancer and Anti-Cancer Strategies DOI Creative Commons
Αλέξανδρος Τσούπρας,

Theodora Adamantidi,

Marios Argyrios Finos

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2024, Volume and Issue: 29(10)

Published: Sept. 26, 2024

Since 2000s, we have outlined the multifaceted role of inflammation in several aspects cancer, via specific inflammatory mediators, including platelet activating factor (PAF) and PAF-receptor (PAFR) related signaling, which affect important junctions cellular interactions that are associated with tumor-related manifestations. It is now well established disease-related unresolved chronic responses can promote carcinogenesis. At same time, tumors themselves able to their progression metastasis, by triggering an inflammation-related vicious cycle, PAF its signaling play crucial role(s), usually conclude tumor growth angiogenesis. In parallel, new evidence suggests also interact cancer treatments inducing antitumor immune response or, conversely, promoting recurrence. Within this review article, current knowledge future perspectives implication all these thoroughly re-assessed. The potential beneficial PAF-inhibitors natural or synthetic modulators PAF-metabolism against tumors, metastasis evaluated. Emphasis given molecules dual anti-PAF anti-cancer activities (Bio-DAPAC-tives), proven potency through clinical trials, as on metal-based anti-inflammatory mediators constitute a class potent inhibitors. way compounds may anti-tumor effects modulate actions discussed. Limitations targeting PAF, metabolism receptor, PAF-related part(s) strategies involve response(s) for improved outcome,

Language: Английский

Re-Assessing the Role of Platelet Activating Factor and Its Inflammatory Signaling and Inhibitors in Cancer and Anti-Cancer Strategies DOI Creative Commons
Αλέξανδρος Τσούπρας,

Theodora Adamantidi,

Marios Argyrios Finos

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2024, Volume and Issue: 29(10)

Published: Sept. 26, 2024

Since 2000s, we have outlined the multifaceted role of inflammation in several aspects cancer, via specific inflammatory mediators, including platelet activating factor (PAF) and PAF-receptor (PAFR) related signaling, which affect important junctions cellular interactions that are associated with tumor-related manifestations. It is now well established disease-related unresolved chronic responses can promote carcinogenesis. At same time, tumors themselves able to their progression metastasis, by triggering an inflammation-related vicious cycle, PAF its signaling play crucial role(s), usually conclude tumor growth angiogenesis. In parallel, new evidence suggests also interact cancer treatments inducing antitumor immune response or, conversely, promoting recurrence. Within this review article, current knowledge future perspectives implication all these thoroughly re-assessed. The potential beneficial PAF-inhibitors natural or synthetic modulators PAF-metabolism against tumors, metastasis evaluated. Emphasis given molecules dual anti-PAF anti-cancer activities (Bio-DAPAC-tives), proven potency through clinical trials, as on metal-based anti-inflammatory mediators constitute a class potent inhibitors. way compounds may anti-tumor effects modulate actions discussed. Limitations targeting PAF, metabolism receptor, PAF-related part(s) strategies involve response(s) for improved outcome,

Language: Английский

Citations

4